The PDCD1 (rs2227981) TT genotype has been shown to be associated with increased irAEs in an exploratory cohort of 181 patients with NSCLC who received nivolumab, but this was not reproducible in the validation cohort (OR 0.92; 95% CI 0.45–1.90; p = 0.828) [77]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.